Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Alkeus Pharmaceuticals has raised $150 million via a Series B round in order to advance a precision medicine candidate to treat Stargardt disease, a currently incurable genetic disease that causes blindness in children and young adults.

The news, announced Monday, said that the financing would go toward pushing the drug candidate, gildeuretinol, towards the FDA and to NDA submission. The financing will also be used to expand the company — but exact specifics weren’t disclosed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

Bain leads $150M round to push blind­ness biotech's rare dis­ease drug to­ward FDA

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them